Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011849 (
diabetes
)
277,896
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The rate-limiting enzyme in insulin-mediated nonoxidative glucose disposal, glycogen synthase, has reduced activity in insulin-resistant subjects at risk for developing non-insulin-dependent
diabetes mellitus
(NIDDM). The synthase-activating enzyme, type 1 protein phosphatase (PP1), also has an abnormally low level of activity. Inhibitor 2 (I-2) reversibly inhibits and facilitates the proper conformation of free catalytic subunits of PP1. This study investigates whether genetic alteration(s) in the I-2 coding locus (
PPP1R2
) could contribute to insulin resistance in Pima Indians. We determined that the authentic
PPP1R2
gene is located on chromosome 3q29 and consists of six exons. The previously reported homologue of
PPP1R2
on chromosome 5 is identified as an intronless pseudogene. Comparative sequencing of
PPP1R2
exons and splice junctions revealed no mutations in insulin-resistant Pima Indians. The information on the genomic structure of
PPP1R2
is important for exploring this gene as a potential candidate contributing to insulin resistance and NIDDM in other populations.
...
PMID:Genetic analysis of human type 1 protein phosphatase inhibitor 2 in insulin-resistant Pima Indians. 912 90
